Olaparib, an inhibitor of poly (ADP-ribose) polymerase (PARP), has demonstrated promising outcomes in treating HER2-negative early-stage breast cancer with BRCA mutations. However, a comprehensive ...

On March 28, the FDA approved Imfinzi for use in combination with gemcitabine and cisplatin as neoadjuvant treatment, followed by single-agent Imfinzi as adjuvant treatment after radical cystectomy, ...

Hormone receptor (HR)-positive HER2-negative advanced breast cancer is incurable and the aim of treatment is to delay it getting worse and extend how long people live. If the cancer has alterations in ...

EU approves expanded use of ABBV's Rinvoq and AZN's Imfinzi and Enhertu. NVS set to invest $23B to boost U.S. manufacturing.

C, provided insights on what to consider when treating patients with HR+, HER2- breast cancer in the second line of treatment ...

Daiichi Sankyo-partnered anti-HER2 drug Enhertu (trastuzumab deruxtecan) has been cleared by the European Commission for use ...

The firm believes VVD-159642 has the potential to treat a broad patient population, including those with RAS- and HER2-overexpressed tumors.

On March 5, 2025, the FDA cleared an investigational new drug application for CTD402, a CD7-targeted universal CAR T-cell therapy, for the treatment of pediatric and adult patients with ...

The FDA approved several therapies in oncology in the month of March 2025. These drugs included treatments for ...

Q4 2024 Earnings Call Transcript March 31, 2025 Celcuity Inc. misses on earnings expectations. Reported EPS is $-0.85 EPS, ...

The current second-line treatment paradigm for HR-positive, HER2-negative patients ... after they've progressed on a CDK4/6 inhibitor. The pricing for drugs today in this, that are proprietary ...

Humira is a type of immunosuppressant known as a tumor necrosis factor (TNF) inhibitor. It's used to treat several types of autoimmune conditions.